Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD

13 Apr 2017

• By Lucie Ellis-Taitt

Related Content

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

06 Jan 2017

Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia

06 Jan 2017

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

30 Aug 2016

Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine

05 Mar 2017

Teva’s Austedo Positioned To Compete With A Generic Rival

04 Apr 2017

Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza

12 Apr 2017

Related Companies

Neurocrine Biosciences, Inc.

Teva Pharmaceutical Industries Ltd.

H. Lundbeck A/S

Auspex Pharmaceuticals, Inc

Synchroneuron, Inc.

Medicure Inc.

Additional Topics

Approvals Business Strategies Commercial Drug Safety Launches Research & Development Pipeline Watch Neurology BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.